A round up of all the latest news on www.globaluniversityventuring.com for our subscribers.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Washington hails $500,000 grant scheme
Washington University in St Louis is to launch grant scheme called Holekamp Seed Fund to back student entrepreneurs with a $500,000 donation from the Holekamp family.
Quethera stars in Astellas acquisition
Glaucoma therapy spinout Quethera will become a unit of drug manufacturer Astellas Pharma, providing exits to investors Cambridge Enterprise, UCEF III and UK2IS.
Millendo overtakes OvaScience in merger deal
Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.
Paragen Bio parachutes into $4.4m
James Cook University has formed its first spinout, Paragen Bio, which will commercialise autoimmune disease therapies derived from a blood-sucking tropical parasite.
Sarepta carries Lacerta through $30m round
Gene therapy developer Lacerta Therapeutics, based at University of Florida’s Sid Martin Biotech incubator, has secured funding from Sarepta Therapeutics.
Bugworks catches $9m series A
Antibiotics developer Bugworks Research has been backed by Utec in its bid to commercialise a treatment for hospital superbugs.
Magnolia colours in $31m series A
Based on research at MD Anderson, Magnolia Neurosciences has launched with funding from corporates AbbVie, Eli Lilly, Pfizer, Johnson & Johnson and WuXi AppTec.
Corporates help plant $150m in Orchard
Orchard Therapeutics’ overall funding has been taken past $290m, three months after the UCL spinout was awarded GUV Deal of the Year for its $110m series B round.
Care Revolution attends to $150,000 round
IU spinout Care Revolution has been backed by the university’s Philanthropic Venture Fund after previously raising funds in 2016.
McQuade researches new CMU position
Michael McQuade will become vice-president for research at Carnegie Mellon in January 2019 after six years as a trustee for the university.
BioBeats sways to $3m rhythm
OSI has backed digital wellness technology company BioBeats, which was founded by University of Surrey faculty and counts multiple corporates among its shareholders.
NDSU unveils Oncothira
Oncothira will develop an oncological asset based on research by Steven Qian in North Dakota State University’s School of Pharmacy.
Sensyne Health senses $76m IPO
Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.
Paterson signs up to Colorado State
David Paterson, once the director of tech transfer at Pennsylvania State University, has rejoined the academic world by accepting a position as assistant vice-president at CSU.
HawkEye 360 preys on $9.6m
Allied Minds has returned to back satellite intelligence gathering technology company HawkEye 360 after having taken part in an $11m round in 2016.
City National pays out for Exactuals acquisition
Financial services firm City National Bank has bought Stanford StartX-backed royalties payment platform Exactuals having led its series B round last year.
Aberdeen helps elevate 14 companies
University of Aberdeen and entrepreneurial training firm Elevator have concluded the latest edition of their Accelerator Aberdeen program.
Pfizer coughs up funding for Biontech
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Healthera administers $3.8m series A dose
Digital prescription platform Healthera has been backed by Cambridge Enterprise, its Seed Funds vehicle and UCEF.


